Davis Lara E, Janeway Katherine A, Weiss Aaron R, Chen Yen-Lin E, Scharschmidt Thomas J, Krailo Mark, Glade Bender Julia L, Kopp Lisa M, Patel Shreyaskumar R, Schwartz Gary K, Horvath L Elise, Hawkins Douglas S, Chuk Meredith K, Reinke Denise K, Gorlick Richard G, Randall R Lor
Knight Cancer Institute, Department of Medicine and Department of Pediatrics, Oregon Health and Science University, Portland, Oregon.
Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts.
Cancer. 2017 Sep 15;123(18):3434-3440. doi: 10.1002/cncr.30757. Epub 2017 May 11.
More than half of all sarcomas occur in adolescents and young adults (AYAs) aged 15 to 39 years. After the publication of the AYA series in the April 1, 2016 issue of Cancer, several leaders in the field of sarcoma across disciplines gathered to discuss the status of sarcoma clinical research in AYAs. They determined that a focused effort to include the underrepresented and understudied AYA population in current and future sarcoma clinical trials is overdue. Trial enrichment for AYA-aged sarcoma patients will produce more meaningful results that better represent the disease's biology, epidemiology, and treatment environment. To address the current deficit, this commentary outlines changes believed to be necessary to expediently achieve an increase in the enrollment of AYAs in sarcoma clinical trials. Cancer 2017;123:3434-40. © 2017 American Cancer Society.
超过半数的肉瘤发生于15至39岁的青少年和青年(AYA)人群中。在2016年4月1日的《癌症》杂志上发表了AYA系列文章后,肉瘤领域各学科的几位领军人物齐聚一堂,讨论AYA人群肉瘤临床研究的现状。他们认定,当下亟需集中力量,将目前在肉瘤临床试验中代表性不足且研究较少的AYA人群纳入进来。针对AYA年龄组肉瘤患者的试验富集将产生更有意义的结果,能更好地体现该疾病的生物学特性、流行病学特征及治疗环境。为弥补当前的不足,本述评概述了一些被认为实现肉瘤临床试验中AYA人群入组增加所必需的变革。《癌症》2017年;123:3434 - 40。© 2017美国癌症协会。